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Responsible use of scarce health 
resources
A great deal could be done to provide more helpful but costly 
medical care if the expenditure on wasteful practices was 
eliminated. This message is reinforced by the findings of three 
papers and an accompanying editorial in this issue of the SAMJ.
The results of a study of the utilisation of pathology 
procedures in the private pathology sector are reported by 
Carel Pretorius (p. 51).  He found that numbers of both test 
procedures and accounts increased during the period of study. 
These increases occurred despite a decrease in the number 
of beneficiaries. The utilisation of individual procedures 
varied between laboratories, with large differences in the 
performance of common tests. The very high incidence of 
ESR per FBC and almost universal creatinine with ‘urea and 
electrolytes’ is a cause of concern, and efforts to decrease 
excessive and inappropriate utilisation of these specific tests 
have been described elsewhere. Variations observed can partly 
be explained by factors under the control of the individual 
laboratories such as the design of the pathology request form, 
the expanding content of profiles and the reflexing of tests such 
as reticulocyte counts. Business opportunities arising from a 
corporate shareholder may also contribute. The submission of 
ICD10 codes as envisaged will be invaluable for the rational 
assessment and management of laboratory test utilisation. 
The most effective way to improve test utilisation is to control 
the design of the pathology request form. It has been shown 
that the absence of ‘tick boxes’ limited profile content and 
individual requesting of tests, reducing pathology expenditure 
without compromising patient care. The temptation to increase 
the number of tests per event will also be removed by removing 
the episode fee component from each individual National 
Health Reference Price List (NHRPL) item and substituting it 
with a single new NHRPL code for an episode fee.
The feasibility and affordability of a targeted screening 
programme for abdominal aortic aneurysms (AAAs) was 
studied by Rothberg, McLeod, Walters and Veller (p. 58) 
using data from 6 participating medical schemes. AAA affects 
between 4% and 8% of males over the age of 65 in a number of 
countries. Most AAAs are asymptomatic, but a percentage will 
rupture without warning. Less than 50% of patients with AAAs 
that rupture will reach hospital alive; emergency surgery in 
these patients costs more and there is an 8 - 10-fold increase in 
postoperative mortality risk. International experience has been 
that screening for AAA reduces morbidity and mortality but 
at a significant cost. On the basis of their findings the authors 
conclude that the considerable cost would be unaffordable for 
most medical schemes in South Africa. 
The Medicines and Related Substances Control Amendment 
Act No. 90 of 1997 (the Act) was designed to enable the 
government to undertake a variety of actions to provide a 
supply of more affordable medicines. This included enabling 
the generic substitution of a branded drug. Deroukakis (p. 63) 
studied the consequences of this by comparing the use of the 
beta-blocker, Tenormin, with three generics. She concludes that 
the aims of the Act have been fulfilled. The greatest increase in 
medical aid claims for generic drugs occurred prematurely, in 
anticipation of the implementation of the law.
In his editorial Burns (p. 38) notes that there has been 
a burgeoning increase of various screening programmes 
driven by the logic that prevention is better than cure. These 
all add substantial costs to a health care system. The cost 
benefit of most such programmes at a community or public 
health level has come under increasing scrutiny and most 
have failed to show convincingly that the positive benefits, 
in terms of decreased mortality, justify the cost, or harm, of 
over-investigation, over-diagnosis or over-treatment. Breast 
screening for cancer for lower-risk patients is controversial, and 
it is clear that routine screening for cancer of the prostate using 
the prostate-specific antigen is not cost beneficial.  
Rolling back malaria in Africa
Malaria is a preventable and treatable disease that affects 
hundreds of millions of people, contributing to a vicious cycle 
of poverty and causing over 1 million deaths each year, with the 
biggest toll in sub-Saharan Africa. The high HIV prevalence in 
sub-Saharan Africa exacerbates human resource constraints by 
increasing the patient caseload while decreasing the workforce. 
An African success story of combating malaria in Eritrea 
is provided in the study by Mufunda et al. (p. 46), and in 
her editorial (p. 36) Karen Barnes enlarges on this theme. A 
range of effective tools is available to achieve ambitious goals 
of reducing mortality due to malaria. Both indoor residual 
insecticide spraying and insecticide-treated bednets have 
been shown to be highly effective for control of the anopheles 
mosquito vector. Early definitive diagnosis can be made using 
rapid diagnostic card tests. Artemesinin-based combination 
therapies are generally considered the current best treatment 
for uncomplicated falciparum malaria. Mortality from severe 
malaria is reduced by 34% with intravenous artesunate when 
compared with intravenous quinine.
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